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Abstract
Background: There is increasing interest in measuring the soluble forms of carbonic anhydrase IX (CA IX) in blood as a marker
of hypoxia for prognostic purposes or for predictive use in therapeutic trials in various cancers. Following our initial
observations of marked differences in the measured concentrations of CA IX in EDTA plasma versus serum, we sought to
investigate these further in order to determine their effects on results in published studies and to ensure accurate
measurement in future studies.
Methods: Serum and EDTA plasma samples from healthy controls and patients with renal cancer were used in the validation
of two commercially available enzyme-linked immunosorbent assays (ELISAs) for CA IX with examination of recovery,
parallelism and speciﬁcity and comparison of paired plasma and serum.
Results: Successful validation of one of the ELISAs was not achieved with particular problems with parallelism and marked
differences in measured CA IX concentrations between EDTA plasma and serum. This appeared to be due to a metal
ion-dependent epitope on CA IX recognized by the detection antibody in this assay. The other commercially available
ELISA examined was successfully validated and showed no difference in CA IX between EDTA plasma and serum.
Conclusions: These results have important consequences for published studies using this assay where the conclusions
drawn from the measurements made may be invalid. This study highlights the need for stringent validation of commercially
available assays, including examination of various sample types, before use in research studies.
Ann Clin Biochem 2011; 48: 112–120. DOI: 10.1258/acb.2010.010240
Introduction
The membrane protein carbonic anhydrase IX (CA IX)
plays a key role in maintaining cellular pH through cata-
lysing the reversible hydration of carbon dioxide to H
þ
and HCO3-, allowing cell survival in hypoxic anaerobic
conditions for example.
1 Aberrant expression in cancer
was initially reported in 1986 with the reactivity of an
antibody clone (G250) with the cell membrane of renal
cell carcinoma cells (RCCs) but not normal renal tissue
2
and subsequent identiﬁcation of the relevant antigen as
CA IX/MN protein.
3,4 With a predicted molecular
weight of 46 kDa, several forms exist through alternative
splicing, proteolytic cleavage, glycosylation and phos-
phorylation.
5–8
CA IX is up-regulated in several cancers
9 due to its regu-
lation by hypoxia-inducible factor-1a (HIF-1a), a key tran-
scriptional regulator of genes involved in the response to
hypoxia.
10 In sporadic conventional (clear cell) RCCs, the
involvement of the Von Hippel Lindau tumour suppressor
gene in most cases
11 also leads to increased expression of
HIF-1a and consequently proteins such as CA IX.
12,13
With its limited expression in normal tissues,
2,7,10 CA IX is
being exploited as a potential therapeutic target using
several strategies including antibody-targeting, vaccine-
based or small molecule inhibitors.
14–17
The potential role of CA IX as a biomarker in RCCs has
been examined in diagnostic imaging using G250.
18
Several immunohistochemical studies have shown the
Annals of Clinical Biochemistry 2011; 48: 112–120prognostic signiﬁcance of CA IX tissue expression, particu-
larly in patients with metastatic disease with low expression
being associated with poorer outcome, although there is dis-
agreement between studies.
9,16 Several initial studies have
also now begun to examine potential clinical utility of
soluble forms of CA IX in the serum or plasma from patients
with RCCs and also other cancers
19–27 both for prognostic
and predictive applications with some interesting but con-
ﬂicting ﬁndings. While validating a commercial enzyme-
linked immunosorbent assay (ELISA) for use in a prognostic
study in RCCs, we found marked differences between the
detectable concentrations of CA IX depending on whether
serum or EDTA plasma was used and report here the sub-
sequent investigations which highlight some important con-
siderations when measuring soluble CA IX.
Materials and methods
Samples
Matched serum and EDTA plasma samples from 17 patients
with RCCs of varying stage and grade (10 men, 7 women;
age range, 42–75 y) and 10 healthy controls (4 men, 6
women; age range 21–66 y) were selected for this study.
Different but overlapping subsets of these samples were
used for the various parts of the assay validation as indi-
cated in each area. All samples had been obtained in
Leeds during 2006–2010 with informed consent and follow-
ing approval by a local research ethics committee.
Venepuncture was carried out using the Vacuette
w
system (Greiner Bio-One, Frickenhausen, Germany), using
Z/serum clot-activator tubes (coated with micronized
silica particles) and EDTA plasma tubes (coated with
1.8 mg/mL K2EDTA). Samples were maintained at room
temperature (208C) postvenepuncture for 45 min before cen-
trifugation at 2000g at 208C for 10 min. Serum and plasma
were aspirated, aliquoted and stored at 2808C until used.
CA IX ELISAs
Initially the commercially available human MN/CA IX
ELISA kit from Oncogene Science/Siemens Healthcare
Diagnostics Inc. (Cambridge, MA, USA) with a stated use
of either serum or plasma (citrate, heparin or EDTA) was
the main focus of the validation, with our intended use
being with EDTA plasma samples. However, following
some of the initial ﬁndings, validation and sample analysis
was also undertaken using the Quantikine human CA IX/
CA9 ELISA kit from R&D Systems (Minneapolis, MN,
USA) as a comparator. In both cases, the ELISAs consist
of sandwich format 96-well plate assays using a mono-
clonal–polyclonal (directly conjugated) format in the case
of the R&D assay compared with a monoclonal-biotinylated
monoclonal format with additional streptavidin-horse-
radish peroxidase conjugate in the case of the Siemens
assay. Samples were assayed in duplicate according to the
manufacturers’ protocols. The sensitivities (Limit of
Detection) of the Siemens and R&D assays as quoted by
the manufacturers are 2.5 and 2.28 pg/mL with a standard
curve range up to 750 (all standards in the Siemens assay
have been prediluted 2-fold similar to the recommended
sample dilution and allowing direct readout of sample
results without correction for dilution – for example, the
top standard in the Siemens assay is actually labelled as
1500 pg/mL) and 1000 pg/mL respectively. Assay-speciﬁc
quality control (QC) samples were run on each plate.
Assay validation
Comparison of EDTA plasma versus serum
The original intention was to validate the Siemens assay for
use with EDTA plasma as our sample of choice but we ﬁrst
investigated if similar results were obtained with both
serum and plasma. Matched pair EDTA plasma and
serum samples (n ¼ 15; 8 RCCs, 7 control) were analysed
using the Siemens assay and subsequently the R&D
Systems assay.
Comparison of assay standardization
Standards provided with the Siemens kit were assayed on
the R&D ELISA using the appropriate diluents and the con-
centrations determined. The converse analysis was also
undertaken. The range of the standards used in each case
was different and determined by the differing ranges of
the two ELISAs. In addition, puriﬁed recombinant CA IX
(R&D Systems) was also measured using both assays.
Intra- and inter-assay precision
For each assay, intra-assay precision was determined by
assessing three QC samples covering the high, mid and
low range of the standard curves six times across a plate.
Inter-assay precision was determined by assessing each
QC sample across three different plates with duplicate
wells for each determination.
Parallelism assessment
Two serum samples and three plasma samples (R&D assay)
and two plasma and one serum sample (Siemens assay)
were serially doubly diluted a further three times over
and above the initial normal dilution for analysis using
the appropriate dilution buffer for each assay and assessed
for parallelism against the standard curves. For the Siemens
assay, a further three EDTA plasma samples were also later
tested in the presence of excess EDTA (þ10 mg/mL ﬁnal
additional concentration) following spiking of the samples
with stock EDTA.
Recovery assessment
Stock solutions of recombinant CA IX (rCA IX) in 0.1% w/v
HSA (Sigma-Aldrich, Poole, UK) were prepared using the
appropriate assay sample diluents to achieve concentrations
10-fold higher than the required ﬁnal spike concentrations
(see below). rCA IX was spiked into samples at 10% of
sample volume and the results were compared with
samples spiked with diluent alone. Five matched pairs of
serum and plasma samples were examined in the R&D
assay. For the Siemens assay three EDTA plasma samples
only were used, as at this time the issues with using serum
in this assay had been identiﬁed. Additionally, recovery was
examined in the presence of excess EDTA (11.8 mg/mL)
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determined taking into account the different standardization
of each assay. Low spikes were aimed at providing an increase
in CA IX concentration of 100 pg/mL in the Siemens assay
and 200 or 250 pg/mL in the R&D assay. High spikes were
aimed at providing an increase in CA IX concentration of
400 pg/mL in the Siemens assay and 600 or 750 pg/mL in
the R&D assay. Absolute concentrations of the spikes used
for the recovery calculations were also checked by spiking
into diluent buffer and assaying in parallel. Percentage recov-
ery was calculated as (ﬁnal concentration 2 initial concen-
tration)/added concentration)   100.
Speciﬁcity
The speciﬁcity in terms of cross-reactivity with other
members of the CA family was assessed by analysing
recombinant CA II and CA XII at 1500 pg/mL in both
assays.
Investigation of the effect of metal ions
on CA IX measurement
To investigate the apparent differences in results obtained
between EDTA plasma and serum in the Siemens assay,
stock CaCl2 and MgCl2 solutions (400 mmol/L) and dipo-
tassium EDTA (36, 50 and 100 mg/mL) were prepared
using Milli-Q water. CaCl2 (and subsequently MgCl2 in
some cases) solutions were spiked (1 in 20) to a ﬁnal concen-
tration of þ20 mmol/L into an RCC serum sample and
three RCC EDTA plasma samples (to generate ‘serum’
in vitro from plasma – plasma treated in this way clotted
and was centrifuged at 1000g for 10 min to separate the
resultant ‘serum’ from the clot). Conversely, EDTA
(36 mg/mL) was spiked (1 in 20) to a ﬁnal concentration
of 1.8 mg/mL into a serum sample and analysed. The
degree of saturation of the effect of EDTA contained
within the EDTA blood tubes was also investigated by
adding further EDTA (þ10 mg/mL) to EDTA plasma
samples (4 normal and 6 RCCs). The reversibility of the
effects of EDTA/metal ions was also checked by spiking
EDTA plasma as above with CaCl2 to promote clotting fol-
lowed by addition of EDTA. All samples were compared
with samples spiked with Milli-Q water. These experiments
were subsequently repeated using recombinant CA IX
where stock solutions of 250–500 pg/mL rCA IX were
spiked with EDTA (ﬁnal concentration þ1.8 mg/mL) or
CaCl2 as above.
Determination of which antibody–antigen interaction
is affected by metal ions
In view of the results showing a metal ion-dependence of
CA IX measurement in the Siemens assay, a crossover exper-
iment was undertaken to determine which antibody was
responsible for this effect. Assays were run in parallel for
both R&D and Siemens assays using six columns of the
12-column format kits in each case. The ﬁrst four columns
in each case contained the appropriate standard curves,
QC samples and four matched serum/EDTA plasma
samples, all examined in duplicate. For the next two
columns of the plate, the capture antibody wells were
exchanged between the assays and the same four matched
pairs of serum/EDTA plasma samples analysed.
Preliminary analyses had been undertaken to show that
the capture antibodies could be exchanged between kits in
this way with minimal effect on the assay background
and compatibility in terms of the new antibody pairs still
allowing detection of CA IX and producing absorbance
signals within the working range of the assay.
Data analysis
Analysis of replicates and inter-/intra-assay precision was
performed by calculating the coefﬁcient of variation
(%CV). The signiﬁcance of the differences between paired
plasma and serum samples was performed using paired
Student’s t-test. Parallelism was determined by back calcu-
lating the concentration of the individual dilutions and
assessing the %CV between the four back-calculated con-
centrations (pass criteria ,15%).
28 Statistical analyses
were conducted using SPSS (v16.0) and GraphPad Prism
(v5) software.
Results
Assay validation
Typical standard curves are shown (Figures 1a and b).
Analysis of rCA IX on both assays showed a ratio of
Siemens:R&D values obtained of 2.8. In support of this indi-
cating differences in standardization, analysis of ﬁve
Siemens standards (35–750 pg/mL) on the R&D assay
showed concentrations ranging from 12.0 to 236.1 pg/mL,
respectively, with an average ratio of Siemens:R&D values
of 3.13 (SD 0.17). Conversely, a reciprocal analysis analysing
three R&D standards (62.5–250 pg/mL assigned concen-
trations) on the Siemens assay showed concentrations
ranging from 154.7 to 626.5 pg/mL, respectively, with an
average ratio of Siemens:R&D values of 2.51 (SD 0.03).
These support the difference seen with the puriﬁed recom-
binant protein with slight differences presumably due to
differing backgrounds with the different standards across
the two assays. However, subsequent comparison of 15
plasma samples across both assays showed no such simple
relationship between assay results with Siemens:R&D ratios
varying from 1.95 to 17.3. Similarly, comparison of the 15
matched serum samples across both assays showed ratios
varying from 0 to 7.1 (Figures 1c and d). These results
support a difference in standardization between assays but
also indicate that with clinical samples there are other poten-
tial factors affecting the results.
Intra-and inter-assay precision was acceptable for both
assays at ,10% with the exception of the lowest concen-
tration controls on the Siemens assay, which exhibited
CVs of 14.5% and 18.6%, respectively (Table 1). Generally
for both assays the SD of the duplicates for any sample
was ,5% of the mean result. The criteria for assessing par-
allelism are described above in the Data analysis section.
Using these criteria, the three samples initially tested on
the Siemens assay failed to dilute out in parallel
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samples were tested in the presence of excess EDTA, this
was still the case with one of the three passing. For the
R&D assay, one sample had extremely low concentrations
of CA IX and was unsuitable but the remaining two
serum and three EDTA plasma samples all passed on paral-
lelism, three of which were among the samples analysed on
the Siemens assay (Figure 2b).
Recovery was acceptable (within the range 80–120%) for
all EDTA plasma samples tested on the Siemens assay and
on the R&D assay (Table 2). However, one of ﬁve serum
samples failed in recovery (,80%) of both high and low
spikes on the R&D assay. Cross-reactivity with CA II and
CA XII was minimal/non-existent when tested using stock
solutions of 1500 pg/mL, producing results of 3.6 and
10.5 pg/mL, respectively, on the Siemens assay and
undetectable and 3.4 pg/mL on the R&D assay.
Measurement of CA IX
Comparison of EDTA plasma and serum concentrations of
CA IX in 15 matched pair samples showed signiﬁcantly
higher concentrations in EDTA plasma samples compared
with serum (P , 0.001) when measured using the Siemens
assay and although a signiﬁcant correlation was seen
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Figure 1 Representative examples of standard curves for the (a) Siemens (corrected for pre-dilution) and (b) R&D assays. (c) and (d) Relationship between con-
centrations of CA IX in 15 matched pairs of EDTA plasma or serum, respectively, using these two assays. The dotted line in each case is the line of equivalence.
CA, carbonic anhydrase
Table 1 Intra- and inter-assay precision for the Siemens and R&D
Systems ELISAs for carbonic anhydrase IX
Intra-assay precision Inter-assay precision
Assay
Mean
conc.
(pg/mL) n SD
CV
(%)
Mean
conc.
(pg/mL) n
conc.
SD
CV
(%)
Siemens 136.0 6 19.7 14.5 145.9 3 27.1 18.6
284.8 6 20.4 7.2 289.7 3 25.7 8.9
728.0 6 29.1 4.0 742.8 3 36.7 4.9
R&D 150.5 6 5.8 3.8 140.1 3 11.7 8.4
288.8 6 21.6 7.5 271.4 3 22.4 8.3
548.4 6 28.5 5.2 523.5 3 42.8 8.2
ELISA, enzyme-linked immunosorbent assay; CV, coefﬁcient of variation
The intra-assay results were derived from analysis of six replicates of each
QC sample with the inter-assay results being based on three separate
measurements each in duplicate
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2 ¼ 0.961), the slope of the line was only 0.538
with several samples lying distantly (Figure 3a). Using the
Siemens assay, concentrations in EDTA plasma ranged
from 34.5 to 1476.4 pg/mL (mean 305.8 pg/mL), while
concentrations in serum were ,2.5 to 770.6 pg/mL (mean
127.9 pg/mL). In contrast, no signiﬁcant difference
between the two sample types was found using the R&D
assay and a signiﬁcant correlation (P, 0.001; r
2 ¼ 0.998)
and a slope of 0.905 were seen (Figure 3b). Using the
R&D assay, concentrations in EDTA plasma were 17.7 to
482.9 pg/mL (mean 91.3 pg/mL) and concentrations in
serum were 18.2 to 436.6 pg/mL (mean 87.4 pg/mL).
Effect of metal ions
As initially we were only using the Siemens assay, ﬁrst
investigations focused on clotting events causing the appar-
ent reduction in measurable CA IX in serum rather than this
being assay-speciﬁc. Spiking of EDTA plasma with excess
calcium, which resulted in clot formation and therefore for-
mation of serum in vitro, did result in a reduction in CA IX
concentrations detected almost to those found in matched
serum samples (n ¼ 3; mean 172.0, SD 75.6 versus mean
83.7, SD 55.8 pg/mL; P ¼ 0.036) supporting this possibility
(Figure 3c). However, addition of EDTA to serum produced
a marked elevation of CA IX detected (Figure 3d) and this
apparent reversibility of the changes was completely
demonstrated in two of the three samples when addition
of calcium to plasma was followed by addition of EDTA
(Figure 3d). This was also seen with recombinant CA IX.
These results clearly show that clotting per se did not
account for the differences but that metal ions may be the
cause. Magnesium produced similar effects to calcium and
importantly the concentration of EDTA in plasma from the
collection tube was found not to be present in sufﬁcient
excess, as further addition of EDTA (þ10 mg/mL) resulted
in further increases of CA IX detected (P, 0.038; n ¼ 7),
although little difference was seen between þ5 and
þ10 mg/mL. As expected, no effects of calcium or EDTA
addition were seen in the R&D assay where differences in
plasma and serum were not observed, which also supports
this explanation.
When capture antibodies were exchanged between
assays, it was very apparent that introduction of the
Siemens capture antibody into the R&D assay maintained
the absence of difference in absorbance values in plasma
versus serum. However, pairing the R&D capture antibody
with the Siemens detection antibody resulted in marked
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Figure 2 Assessment of parallelism in the (a) Siemens and (b) R&D ELISAs for EDTA plasma and serum samples (open symbols ¼ serum; closed symbols ¼
plasma) by comparing the back-calculated concentrations against serial doubling dilutions of the samples. The arrow in each case indicates the normal
working dilution used in the assay. ELISA, enzyme-linked immunosorbent assay
Table 2 Recovery of recombinant carbonic anhydrase (CA) IX spiked into EDTA plasma and serum samples and measured using either the
Siemens or R&D assays
EDTA plasma Serum
Assay Sample
Initial CA IX
(pg/mL)
% recovery (low
spike)
% recovery (high
spike)
Initial CA IX
(pg/mL)
% recovery (low
spike)
% recovery (high
spike)
Siemens 1 516.5 102.2 88.4
2 830.9 93.3 81.0
3 485.1 94.1 88.2
R&D 4 483.3 81.7 80.2 502.4 59.4 66.7
5 92.4 82.3 86.3 92.7 86.7 84.9
6 26.9 81.7 83.0 27.4 81.5 91.2
7 47.6 82.0 91.5 53.2 89.9 93.5
8 84.0 97.8 90.7 88.0 94.0 86.6
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seen in the Siemens assay (Figure 4). This clearly indicates
that the Siemens detection antibody i.e. the M75 clone
29 is
responsible for the differences seen in CA IX in plasma
and serum and together with the previous results is consist-
ent with the recognition by this antibody of an epitope
which is metal-ion dependent.
Discussion
There is a substantial need for new biomarkers in RCCs and
CA IX is of potential interest. Both plasma and serum con-
centrations of soluble CA IX are reportedly elevated in
RCCs, although reports vary with both a positive correlation
with tumour size and no correlation being reported and a
decrease postsurgery in some patients.
20,21,23 A study of 91
patients with conventional RCCs found that serum CA IX
was signiﬁcantly associated with recurrence-free survival.
19
However, a recent study of serum samples from 287 RCC
patients failed to ﬁnd a signiﬁcant prognostic association
with soluble CA IX, although it was positively correlated
with stage and higher concentrations were also found in
clear cell compared with papillary subtypes.
26 Analysis of
samples from a subset of 66 patients with advanced RCCs
randomized to either sorafenib treatment or placebo
(TARGET) reported that plasma CA IX was prognostic for
overall survival although not of independent signiﬁcance,
and was unchanged and not associated with beneﬁt from
treatment.
27
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used to measure CA IX and clearly we show that there are
marked differences in the performances of two commer-
cially available ELISAs, with one in particular (Siemens)
generating different results depending on whether EDTA
plasma or serum was used. Results in the manufacturer’s
kit insert showed a possible trend, although non-signiﬁcant
and not as marked as reported here but only 10 samples
were examined and all from healthy volunteers. Our
results clearly show that the R&D Systems ELISA is suitable
for use with EDTA plasma and serum and performs accep-
tably, although further recovery studies, conﬁrmation of the
sensitivity and examination of other relevant preanalytical
factors are needed. In contrast, although the Siemens
ELISA passed several elements of the validation assessment,
there were issues with lack of parallelism which to some
extent may be due to our ﬁnding of the importance of
metal ions on the concentration of CA IX measured. This
latter effect meant that by adding calcium or removing
metal ions through the use of chelating agents such as
EDTA, the concentration detected could be varied reversi-
bly. Although the calcium concentration used here was
excess rather than physiological to promote clotting, it is
likely that variations in the physiological range could inﬂu-
ence the measurement still as further addition of calcium to
serum resulted in further reductions. Similarly, the amount
of EDTA present in blood collection tubes as an anticoagu-
lant did not appear to have saturated the chelating effect,
implying that even in EDTA plasma accurate determination
was not guaranteed. Clearly, variability in ﬁlling of the
blood tube at venepuncture with consequent effects on
ﬁnal EDTA concentration would also contribute to further
variation.
At least two forms of soluble CA IX have been described
(50 and 54 kDa) formed by cleavage of the extracellular
region of CA IX.
20 This region contains a negatively
charged N-terminal proteoglycan-like (PG) domain and
the CA catalytic domain, which has three metal binding
regions to which zinc is known to bind and which is essen-
tial for the catalytic activity.
30 The M75 detection antibody
in the Siemens assay recognizes a linear epitope (containing
the repeat motif of GEEDLP) on the PG domain
31 whereas
the V10 capture antibody targets a conformational epitope
on the CA domain.
6,32 Recent evidence also supports the
binding of multiple divalent cations to the highly negatively
charged PG domain with an effect on the catalytic activity of
CA IX.
5 Our study provides further indirect evidence for
this as the M75 antibody, which binds to this domain and
which appears to be responsible for the effects seen in our
study with plasma and serum, appears to bind to an
epitope which is metal ion-dependent. These effects may
be mediated by direct inhibition of M75 competitively or
through induction of a conformational change.
Several of the previously discussed studies have used the
R&D Systems assay and under conditions that are likely to
have produced robust results. However, several studies in
renal cancer but also in ovarian, lung and bladder cancers
have either used the Siemens assay or assays involving the
M75 antibody
20,22–25,27 and the results may therefore be
affected as described here. Oncogene Science/Siemens
Healthcare Diagnostics Inc. was provided with a summary
of the results reported in this paper. The M75 antibody
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immunohistochemically and there is the very real possibility
that buffers used in such studies may inﬂuence the results
seen, which warrants further investigation.
Although differences in concentrations of analytes
between plasma and serum have been shown previously
due to effects of clotting, for example higher serum concen-
trations of vascular endothelial growth factor due to release
by platelets
33 or lower serum concentrations of osteopontin
due to cleavage during clotting,
34 the phenomenon
described here where differences in measured levels are
due to metal ion-dependence of the speciﬁc epitope recog-
nized by an antibody in an assay is much less well
described. Examples include the calcium dependence of cal-
retinin measurements possibly analogous to this study,
35
elimination of false-positive results in the RSR GADAb
ELISA by adding calcium to EDTA plasma possibly by
effects on proteases
36 and the lower concentrations of
S100A12 in EDTA plasma possibly due to loss of oligomer-
ization and consequent antibody binding in the absence of
calcium.
37 Such studies illustrate the need for careful inde-
pendent validation of commercially available immunoas-
says prior to use in research studies to avoid erroneous
conclusions regarding potential clinical utility and wasted
resources.
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